<DOC>
	<DOCNO>NCT01987596</DOCNO>
	<brief_summary>This randomized phase III trial study flexible administration filgrastim combination chemotherapy see well work compare fixed administration filgrastim decrease side effect chemotherapy young patient cancer . Cancer chemotherapy frequently result neutropenia ( low blood count ) patient susceptible severe infection . A medicine call G-CSF ( filgrastim ) stimulate bone marrow daily filgrastim shot commonly use shorten neutropenic period decrease infection chemotherapy . Since filgrastim customarily use fixed schedule start early chemotherapy data early dos may need , study test new flexible schedule filgrastim optimize use reduce number painful shot , cost treatment , filgrastim side effect child cancer receive chemotherapy .</brief_summary>
	<brief_title>Study Fixed v . Flexible Filgrastim Accelerate Bone Marrow Recovery After Chemotherapy Children With Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare effect flexible vs. fix administration G-CSF ( filgrastim ) parameter hematological recovery include duration absolute neutrophil count ( ANC ) &lt; 500/uL ; time ANC recovery &gt; = 1,000/uL time platelet recovery &gt; = 75,000/uL child receive myelotoxic chemotherapy . SECONDARY OBJECTIVES : I . To compare effect flexible vs. fix administration G-CSF incidence febrile neutropenia number hospital day antibiotic follow myelotoxic chemotherapy . II . To evaluate number day platelet transfusion event chemotherapy cycle flexible vs. fix administration G-CSF . III . To evaluate incidence duration G-CSF-related side effect include extremities/back pain headache chemotherapy course follow flexible vs. fix administration G-CSF . IV . To evaluate peripheral blood progenitor response subset progenitor cell ( cluster differentiation [ CD ] 34/41/61/117/10/19/11b/33 ) chemotherapy follow flexible vs. fix administration G-CSF . OUTLINE : CHEMOTHERAPY : Depending diagnosis patient assign 1 3 chemotherapy regimen . ICE : Patients receive etoposide intravenously ( IV ) 1 hour day 1-3 , ifosfamide IV 3 hour day 1-3 , carboplatin IV 1 hour day 4 . Patients recurrent Hodgkin lymphoma receive etoposide ifosfamide day 1-3 carboplatin day 3 . ICT : Patients receive topotecan hydrochloride IV 30 minute day 1-3 , ifosfamide carboplatin ICE . OPEC : Patients receive vincristine sulfate day 1 , 8 , 15 ; etoposide IV 1 hour day 1-3 ; cyclophosphamide IV 1 hour day 1-2 ; cisplatin IV 6 hour day 4 . For chemotherapy regimen , treatment repeat every 21 day 2 course . Patients randomize 1 2 treatment arm . ARM I ( fix filgrastim ) : Patients receive filgrastim subcutaneously ( SC ) daily ( QD ) start 24 hour completion chemotherapy stop ANC reach least 1,000/uL post nadir . ARM II ( flexible filgrastim ) : Patients receive filgrastim SC QD start first day chemotherapy ANC fall 1,000/uL stop ANC reach least 1,000/uL post nadir . After completion first filgrastim treatment , patient cross-over filgrastim arm repeat course chemotherapy . After completion second filgrastim treatment , chemotherapy treatment may continue 5 ( OPEC ) 6 ( ICE , ICT ) course absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Retinoblastoma</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Choroid Plexus Neoplasms</mesh_term>
	<mesh_term>Pinealoma</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Subjects must initial diagnosis , histologic proof malignancy ; young child primary embryonal brain tumor treat accord Head Start protocol eligible ; subject bone marrow involvement NOT eligible study Patients receive repeat cycle identical chemotherapy likely result grade IIIIV hematological toxicity ; patient treat outside Children 's Oncology Group ( COG ) protocols specific requirement schedule GCSF administration ; follow category patient treat Children 's Hospital Michigan eligible study : Patients brain tumor treat accord Head Start II protocol vincristine , etoposide , cyclophosphamide , cisplatin ( OPEC ) chemotherapy ; Patients recurrent Hodgkin lymphoma treat ICE ( ifosfamide , carboplatin , etoposide ) chemotherapy ; Patients recurrent solid tumor include sarcoma , Wilms ' tumor , neuroblastomas , brain tumor treat high dose ICE ICT ( ifosfamide , carboplatin , topotecan ) chemotherapy Patients UH Wilms ' tumor treat CE ( cyclophosphamide , etoposide ) ; patient neuroblastoma treat CE ( carboplatin , etoposide ) ; Patients soft tissue sarcoma treat IA ( ifosfamide , doxorubicin ) ; Patients osteosarcoma treated high dose ifosfamide Subjects must fully recover toxic effect prior therapy ; least 3 week elapse since last dose chemotherapy ( 6 week case nitrosourea contain therapy ) ; subject must recover previous colonystimulating factor therapy colonystimulating factor ( GCSF , granulocyte macrophage colonystimulating factor [ GMCSF ] , interleukin [ IL ] 11 ) 10 day erythropoietin 30 day ANC &gt; 1000/uL Platelet count &gt; 100,000/uL Creatinine clearance glomerular filtration rate ( GFR ) great equal 70 ml/min/1.73 m^2 Bilirubin le 1.5 x normal limit ( NL ) Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) less 2.5 x NL age Subjects normal ejection fraction ( per institutional limit ) , evidence cardiac arrhythmia require therapy , fractional shortening &gt; 28 % All subject must life expectancy 12 week Diagnostic category Sarcoma ( soft tissue bone ) Kidney tumor Brain tumor Other solid tumor ( gonadal germ cell tumor , retinoblastoma , neuroblastoma , miscellaneous tumor ) Hodgkin lymphoma Performance status must &gt; 60 Lansky ( age 1 16 ) Karnofsky ( age &gt; 16 ) Subjects follow NOT eligible study : Bone marrow involvement Active myelogenous leukemia , history myelogenous leukemia Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>